ABALOS THERAPEUTICS

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system's power specifically against cancer cells. Through viral replication within cancer cells, Abalos' arenavirus-based drug candidates are designed to awake precise immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos' goal is to achieve a quantum leap in immuno-oncology... Our scientific founders, immunology and virology experts Karl Lang and Philipp Lang, identified a specific set of mammarenaviruses that preferentially infect and proliferate in cancer cells, which results in a very strong and targeted immune response against the cancer. Abalos is translating these findings into a novel therapeutic strategy to enable a precise immune response and activate all relevant immune cell types against..

Also known as: Abalos, Abalos Therapeutics GmbH

VAT numbers: DE325061608

Primary location: Düsseldorf